Sionna Therapeutics (NASDAQ:SION - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.17), Zacks reports.
Sionna Therapeutics Price Performance
SION opened at $12.32 on Monday. Sionna Therapeutics has a one year low of $7.26 and a one year high of $25.19. The firm's 50 day simple moving average is $12.25.
Analyst Ratings Changes
SION has been the topic of several research reports. TD Cowen initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating on the stock. Guggenheim initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $45.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $32.00 price objective on the stock.
Read Our Latest Analysis on SION
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
